Viking Therapeutics (VKTX) EPS (Weighted Average and Diluted) (2017 - 2025)
Historic EPS (Weighted Average and Diluted) for Viking Therapeutics (VKTX) over the last 8 years, with Q3 2025 value amounting to -$0.81.
- Viking Therapeutics' EPS (Weighted Average and Diluted) fell 26818.18% to -$0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.12, marking a year-over-year decrease of 12795.7%. This contributed to the annual value of -$1.01 for FY2024, which is 1098.9% down from last year.
- Per Viking Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.81 for Q3 2025, which was down 26818.18% from -$0.58 recorded in Q2 2025.
- Viking Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$0.16 for Q4 2021, and its period low was -$0.81 during Q3 2025.
- In the last 5 years, Viking Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.23 in 2022 and averaged -$0.29.
- As far as peak fluctuations go, Viking Therapeutics' EPS (Weighted Average and Diluted) surged by 1739.13% in 2023, and later crashed by 26818.18% in 2025.
- Viking Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.16 in 2021, then plummeted by 62.5% to -$0.26 in 2022, then increased by 3.85% to -$0.25 in 2023, then fell by 28.0% to -$0.32 in 2024, then crashed by 153.12% to -$0.81 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.81 for Q3 2025, versus -$0.58 for Q2 2025 and -$0.41 for Q1 2025.